Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...

Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment. The company ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...

The European Medicines Agency asked for three clinical trials to be placed on hold until the exact cause of death of a US ...

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...

The European Medicines Agency has temporarily suspended enrollment and dosing in a Phase II trial of Sarepta Therapeutics' ...

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...